Johnson & Johnson vs ThredUp Inc — how do they compare? Johnson & Johnson trades at $262.21 (market cap $628.65B), while ThredUp Inc trades at $3.17 (market cap $405.82M). The key difference: Johnson & Johnson is far larger — about 1549.1× ThredUp Inc's market cap, and Johnson & Johnson pays a 2.05% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| JNJ | TDUP | |
|---|---|---|
Market Cap | $628.65B | $405.82M |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $12.08 |
52-Week Low | $174.16 | $3.08 |
Enterprise Value | $656.92B | $404.00M |
Dividend Yield | 2.05% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $262.08, up 0.88% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend growth spanning 64 years. Recent earnings show beats in Q1 and Q2 2026, while analysts maintain a buy consensus with a $284.50 price target representing 8.5% upside potential.
JNJ offers stable growth with defensive characteristics but faces headwinds from patent expirations and legal challenges. The stock trades at a premium valuation (P/E 30.26) but justifies it with robust profitability (ROE 25.74%). Current price near 52-week highs suggests limited near-term upside without new catalysts.
ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.
The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →